Articles from Elevai Labs Inc.

NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it completed a strategic reorganization. This reorganization included changing the Company’s name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. Upon this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.

NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company’s name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.

NEWPORT BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (Nasdaq: ELAB) (“Elevai” or the “Company”), a diversified holding company, subsidiary Elevai Biosciences Inc. (“Elevai Biosciences”), today announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass.

NEWPORT BEACH, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (Nasdaq: ELAB) (“Elevai” or the “Company”), a diversified holding company, announces the launch of the S-Series Root Renewal System™ (the “Root Renewal System”), a revolutionary entry into the hair care market by its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai Skincare”). The Root Renewal System is a three-part hair and scalp care system consisting of a shampoo, conditioner and serum that combines the latest in patent pending exosome and mitochondrial technology to target scalp and hair health at the cellular level.

NEWPORT BEACH, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (Nasdaq: ELAB) (“Elevai”, “Elevai Labs” or the “Company”), a diversified holding company, announces that its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai Skincare”), has achieved a record-breaking month in sales for 2024, marking a significant milestone for the Company. This achievement underscores the success of transformational restructuring efforts led by Elevai Labs’ new executive team and the adoption of a performance-driven culture.

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (Elevai" or the "Company") announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock Split”) of its common stock, which will be effective at midnight on November 27, 2024. This initiative aligns with the Company’s efforts to meet Nasdaq's minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2).

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has withdrawn the previously announced offer (the “Offer”) to holders of the Company’s outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company’s newly issued Series B Preferred Stock (“Series B Preferred Stock”), as a result of notice from the Depositary Trust Company (“DTC”) that due to logistical issues, DTC would not be able to accept the tenders of Common Stock. As a result of this withdrawal, no shares will be exchanged in the Offer and all shares previously tendered and not withdrawn will be promptly returned to tendering holders. The Company had intended to complete the Offer prior to a planned reverse stock split; however, unforeseen circumstances, including amending the offering materials in response to Securities and Exchange Commission ("SEC") comments, caused delays. As a result, the Company has withdrawn the Offer to prioritize regaining compliance with Nasdaq's listing requirements.

NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQELAB), please note that in the headline and first paragraph, the financial results are from the company's third fiscal quarter of 2024, not the second fiscal quarter as previously stated; as such, the header over the first bullet list should note the financial results as being from the three and nine months ended September 30, 2024, rather than the three and six months ended June 30, 2024 as previous stated. The corrected release follows:

NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended September 30, 2024 and provided a business update.

NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company’s outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company’s newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock. The terms and conditions of the Offer are described in the Amended and Restated Offer to Exchange dated November 4, 2024 (“Amended and Restated Offer to Exchange”) and the related Letter of Transmittal, as they may be amended or supplemented from time to time (the Amended and Restated Offer to Exchange, together with the Letter of Transmittal, the “Offer Documents”).

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) --

NEWPORT BEACH, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Elevai Biosciences Inc. (“Elevai Biosciences”), a subsidiary of Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), today released encouraging past preclinical data from 2022 for EL-32, a pioneering dual-action blocker targeting myostatin and activin-A. Preclinical results generated from our licensing partner in a 2022 study indicated that EL-32 may offer a breakthrough approach to obesity treatment by simultaneously preserving muscle mass and reducing fat mass when used alongside popular weight loss therapies such as GLP-1 receptor agonists.

NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an offer to exchange up to 15,000,000 shares of its currently issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) for up to 15,000,000 shares of the Company’s newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock. A stockholder who desires to tender Common Stock in this offering must tender all of such stockholder’s Common Stock. The exchange offer will expire at the end of the day, 5:00 P.M., New York City Time, on November 5, 2024, unless extended or withdrawn.

NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the filing of two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. These patent applications cover both standalone and combination therapies using EL-22 alongside GLP-1 receptor agonists, marking a significant advancement in obesity treatment.

NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the filing of two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. These patent applications cover both standalone and combination therapies using EL-22 alongside GLP-1 receptor agonists, marking a significant advancement in obesity treatment.

NEWPORT BEACH, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced the initiation of a clinical study to assess the efficacy of a topical exosome product in conjunction with an energy device treatment on facial skin appearance.

NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.

NEWPORT BEACH, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced positive case study results from patients undergoing laser therapy followed by use of Elevai E-Series for applications in melasma. Elevai believes that these case studies can be the premise for future exosome research on effective melasma solutions.

NEWPORT BEACH, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) --  Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced data results from an on-going research study conducted in partnership with Carly Klein, President of the National Hair Loss Medical Aesthetics (“NHLMA”), demonstrating the potential of its proprietary Elevai Exosomes™ in hair restoration.

NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics announces the filing of two innovative patents in collaboration with Yuva Biosciences. These patents support the development of Elevai’s innovative solutions for hair and scalp vitality. The first patent, “COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN, SCALP, AND HAIR IMPROVEMENT”, Patent Application Serial No 63/664,517, covers the unique and novel combination of Elevai exosomes and Y100, technologies that the inventors believe are synergistic and could allow significantly better results than either technology used alone. The second patent, “PREPARATIONS INCLUDING LIPID BILAYER NANOPARTICLES”, Patent Application Serial No 63/664,526, covers the use of exosomes (and similar lipid bilayer based nanovesicles) as a unique delivery system while also serving to protect and preserve the molecules being delivered.

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity™ to be safe and tolerable with significant improvement noted across many aspects of skin appearance. Elevai aims to publish the full study results in the near future.

NEWPORT BEACH, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced results from an on-going research study in partnership with Dr. Stanislav Sokolenko’s Lab, Associate Professor at Dalhousie University’s Department of Process Engineering and Applied Science, demonstrating the potential of its proprietary Precision Regenerative Exosome Technology™ (“PREx™”) in generating exosomes that carry proteins associated with extracellular matrix organization, immune functions, and wound healing.

NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.

NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, to the Scientific Advisory Board of its subsidiary, Elevai Biosciences Inc. (“Elevai Biosciences”). As a renowned researcher in the field of metabolism, Dr. Shirihai will support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

NEWPORT BEACH, Calif., June 28, 2024 (GLOBE NEWSWIRE) --  ELEVAI LABS, INC. (NASDAQELAB), a pioneering force in medical aesthetics, is excited to announce the introduction of the Elevai S-Series™ hair and scalp care product line through Elevai Skincare, a subsidiary of Elevai Labs.

NEWPORT BEACH, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQELAB) a pioneering force in medical aesthetics, is excited to announce Elevai Skincare’s participation in The Aesthetic Show, taking place on June 27-30, 2024 at the Wynn Las Vegas. The company will be showcasing its latest advancements at Booth #511 and unveiling the next generation of its groundbreaking stem cell exosome products.

NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

NEWPORT BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Jordan R. Plews, PhD has been invited back and will be presenting at the Beauty Through Science conference in Stockholm, Sweden on Thursday May 30, 2024.

NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD will be presenting at the Los Angeles Bioscience Ecosystem Summit Twenty 24 (“LA-BEST”) conference on Thursday May 23, 2024.

NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024.

NEWPORT BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), today highlights results from our licensor’s 2022 preclinical studies evaluating the treatment effect of its recently in-licensed asset, EL-22. EL-22 will primarily be commercialized by Elevai Biosciences, Inc., a biopharmaceutical division of the Company focusing on the development and acquisition of cutting-edge aesthetic medicines. Based on our licensor’s 2022 preclinical data, Elevai believes that EL-22 has the potential to treat obesity in combination with GLP-1 receptor agonists by preserving muscle mass while decreasing fat mass.

NEWPORT BEACH, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced the establishment of two new wholly owned subsidiaries, Elevai Biosciences, Inc., and Elevai Skincare, Inc. These ventures mark a strategic shift towards the development of next-generation aesthetic medicines and efforts to improve the economics of its commercialized exosome skincare brand.

NEWPORT BEACH, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC. (NASDAQELAB) (the “Company”), today announced that it has entered into an exclusive licensing agreement with MOA Life Plus Co., Ltd., (“MOA”) a South Korean corporation, with the aim to develop and commercialize two novel assets for the treatment of obesity and muscle loss prevention.

NEWPORT BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (NASDAQELAB) (“Elevai” or the “Company”), a medical aesthetic company specializing in physician-dispensed skincare, announces significant strides in global distribution and highlights an overview of current agreements.

NEWPORT BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC. (NASDAQELAB) (“Elevai” or the “Company”), a medical aesthetic company specializing in physician-dispensed skin care, is pleased to announce that it has signed an international distribution agreement with ILIA International Ltd. (“ILIA”) covering the country of Taiwan.

NEWPORT BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for the fourth quarter and full year ended December, 31, 2023.

ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers

Utility Patent Covers the formulation for ELEVAI’s flagship exosome-based skin care products

NEWPORT BEACH, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced certain preliminary, unaudited management-prepared financial results for the fiscal year ended December 31, 2023. These results are based on the most current information available to management, are unaudited, and subject to the completion of the Company’s year-end financial reporting processes, reviews, audit, and potential adjustments that might result.

ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQELAB) a medical aesthetic company specializing in physician-dispensed skincare, announces participation in three aesthetic industry conferences in the first quarter of 2024.

Company Records Record Quarterly Revenues

NEWPORT BEACH, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB), a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with Skin Sana Ltd., a Serbian corporation and premier luxury skincare distributor based in Belgrade covering territories that include Serbia, Albania, North Macedonia, Kosovo and Bosnia-Herzegovina. This strategic collaboration is the Company's first in Europe and marks the beginning of a robust relationship bringing Elevai’s topical exosome products to the region.

NEWPORT BEACH, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a licensing agreement with Yuva Biosciences, Inc. to research and develop means to incorporate Yuva Bioscience’s mitochondrial research with ELEVAI’s PREx™ (Precision Regenerative Exosome Technology™) to potentially develop topical skincare formulations that combine mitochondrial biology with Elevai’s human umbilical mesenchymal stem cell derived exosomes.